| Patent application number | Description | Published |
|---|
| 20080199490 | Immunogenic Composition - The present application discloses an immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of all the at least two further bacterial saccharide conjugates. | 08-21-2008 |
| 20080220457 | Serum Bactericidal Assay for N. Meningitidis Specific Antisera - The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular | 09-11-2008 |
| 20080233154 | Vaccine Composition - The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are | 09-25-2008 |
| 20080305127 | Conjugate Vaccines - The invention provides vaccines against | 12-11-2008 |
| 20080311146 | Immunogenic Composition - The present invention discloses an immunogenic composition comprising at least two different isolated staphylococcal polypeptides, each comprising an IgG binding domain. In a further embodiment, the invention discloses a polypeptide comprising: a protein A part including at least one IgG binding domain and an Sbi part including at least one IgG binding domain. | 12-18-2008 |
| 20090010959 | Pneumococcal Polysaccharide Conjugate Vaccine - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 01-08-2009 |
| 20090017059 | Vaccine Comprising Streptococcus Pneumoniae Capsular Polysaccharide Conjugates - The present invention discloses an immunogenic composition comprising | 01-15-2009 |
| 20090017072 | Vaccine - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent | 01-15-2009 |
| 20090041802 | IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising | 02-12-2009 |
| 20090117147 | VACCINES COMPRISING OUTER MEMBRANE VESICLES FROM GRAM NEGATIVE BACTERIA - The present invention relates to the field of vaccine formulation, particularly the field of novel adjuvant compositions comprising outer membrane vesicles (or blebs), and advantageous methods of detoxifying these compositions, and advantageous methods of use of such adjuvants. | 05-07-2009 |
| 20090123499 | VACCINE - The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and more effective for use in human subjects. | 05-14-2009 |
| 20090136541 | IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising at least 2 different | 05-28-2009 |
| 20090155887 | Vaccine Composition - The present invention provides a hyperblebbing non-typeable | 06-18-2009 |
| 20090162394 | VACCINE - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 06-25-2009 |
| 20090175912 | Haemophilus Influenza Outer Membrane Protein and Use Thereof in Vaccination - This invention relates to recombinant bacterial outer membrane proteins comprising one or more LB1(f) peptides from surface-exposed loop 3 of MOMP P5 of non-typeable | 07-09-2009 |
| 20090252759 | IMMUNOGENIC COMPOSITION - The present application relates to an immunogenic composition comprising at least 2 conjugates of | 10-08-2009 |
| 20100021503 | IMMUNOGENIC COMPOSITION - The present application relates to immunogenic compositions comprising Type 5 and Type 8 capsular polysaccharide or oligosaccharide from | 01-28-2010 |
| 20100047287 | OUTER MEMBRANE VESICLES AND USES THEREOF - The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection. | 02-25-2010 |
| 20100074918 | VACCINE - The present invention relates to the field of vaccines and in particular to combination vaccines and co-administration schedules. The present inventor discloses that overuse of CRM in paediatric vaccines can result in bystander immune interference to certain antigens and provide solutions to this problem. | 03-25-2010 |
| 20100074922 | Pneumococcal polysaccharide conjugate vaccine - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 03-25-2010 |
| 20100119544 | VACCINE - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from | 05-13-2010 |
| 20100183662 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition is provided comprising a multivalent | 07-22-2010 |
| 20100209450 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 08-19-2010 |
| 20100239604 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention relates to an immunogenic composition comprising | 09-23-2010 |
| 20100285465 | Molecular Typing of Neisseria Strains by Determining the Presence of Genes Involved in Lipooligosaccharide (LOS) Biosynthesis - The present invention relates to a method of LOS molecular typing of a | 11-11-2010 |
| 20100291137 | METHOD FOR REFOLDING NEISSERIAL NSPA PROTEIN - The present invention provides an isolated refolded NspA protein, and a method of preparing it. | 11-18-2010 |
| 20100291138 | Vaccine - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen form | 11-18-2010 |
| 20100322959 | IMMUNOGENIC COMPOSITION - The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine group on PNAG to form a PNAG conjugate. Methods of using and processes to make an immunogenic composition are also described. | 12-23-2010 |
| 20110008385 | Immunogenic composition - The present application relates to immunogenic compositions comprising staphylococcal PNAG and Type 5 and/or 8 capular polysaccharide or oligosaccharide from | 01-13-2011 |
| 20110008419 | Vaccine Against Streptococcus Pneumoniae - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen from | 01-13-2011 |
| 20110033500 | VACCINE COMPOSITIONS COMPRISING L2 AND/OR L3 IMMUNOTYPE LIPOOLIGOSACCHARIDES FROM LGTB-NEISSERIA MENINGITIDIS - The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB | 02-10-2011 |
| 20110165590 | Vaccine Protection Assay - The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular | 07-07-2011 |
